Michael S. Tanaka, Jr., M.D. 
Clinical/Research Interests
Title:
Specialty:
Center/Program Affiliation:
Address:
4501 X St., Suite 3016
Sacramento, CA 95817
Phone:
Education:
Sacramento, California
M.D. 1982
University of Southern California
Los Angeles, California
B.S. 1976
Internships:
Sacramento, California
1982-1983
Residency:
Sacramento, California
1983-1985
Internal Medicine
Fellowships:
Martinez, California
1986-1991
Hematology/Oncology and Nephrology
Board Certifications:
American Board of Internal Medicine, Medical Oncology, 1989
American Board of Internal Medicine, 1986
Professional Memberships:
American Society of Clinical Oncology
Honors and Awards:
Academic Honor of Hematology, UC Davis, 1980
Academic Honor of Pulmonary Medicine, UC Davis, 1980
Academic Honor of Cardiovascular Medicine, 1980
Magna Cum Laude, USC, 1976
Phi Kappa Phi, USC, 1976
Phi Beta Kappa, USC, 1976
Dean's List, USC, 1972-76
Select Recent Publications:
Ho C, Sangha R, Beckett L, Tanaka M, Lau DH, Eisen DB, Burich RA, Luciw P,Khan I, Mack PC, Gandara DR, Davies AM. Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study. Invest New Drugs. 2011 Aug;29(4):680-7. Epub 2010 Feb 12.
Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009 Sep;64(4):777-83. Epub 2009 Jan 24.
Lau D, Johl J, Huynh M, Davies A, Tanaka M, Lara P, Gandara D. Population-based phase I trial of irinotecan and epirubicin. Am J Clin Oncol. 2008 Jun;31(3):226-30.
Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008 Feb 1;26(4):626-32.
Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara DR. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol. 2007 Dec;2(12):1112-6.
Wang H, Ryu J, Gandara D, Bold R, Urayama S, Goldberg Z, Tanaka M, Follette D, Narayan S and Lau D. A Phase II Study of Paclitaxel, Carboplatin and Radiation with or without Surgery for Esophageal Cancer. J Thorac Oncol, 2007;2(2): 153-157. 2007
Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA, Kugler JW, Benson III AB, Haller DG, Mayer RJ, Atkins JN, Cripps C, Pedersen J, Periman PO, Tanaka Jr MS, Leichman CG, Macdonald JS. Phase III Trial of Fluorouracil-Based Chemotherapy Regimens Plus Radiotherapy in Postoperative Adjuvant Rectal Cancer: GI INT 0144. Journal of Clinical Oncology, 2006 Aug;24(22): 3542-3547. 2006
Whitehead RP, McCoy S, Macdonald JS, Rivkin SE, Neubauer MA, Dakhil SR, Lenz HJ, Tanaka MS, Abbruzzese JL. Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study. Investigational New Drugs. 2006 Jul;24(4):335-41.
